World J Mens Health.
2022 Jan;40(1):66-73. 10.5534/wjmh.210076.
Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
- Narain TA1
- Sooriakumaran P
1,2,3
- Affiliations
-
- 1Department of Uro-Oncology, University College London Hospitals NHS Foundation Trust, UK
- 2Urology Service, Cleveland Clinic London, London, UK
- 3Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- KMID: 2523637
- DOI: http://doi.org/10.5534/wjmh.210076
Abstract
- Prostate specific antigen (PSA) is one of the best-known biomarkers for screening, diagnosis and follow-up of patients for prostate cancer. Owing to several inherent limitations with PSA, various newer blood and urinary based biomarkers have been evaluated in pursuit of better detection and risk stratification of prostate cancer cases. A combination of these different markers, in adjunct with clinical risk factors, and recent advances in imaging promises to offer better diagnostic performance with clearer risk stratification guiding therapeutics. We carried out an extensive literature search for the different biomarkers available for screening and diagnosis of prostate cancer, compared their performance with serum PSA to allow clinicians to draw meaningful conclusions to offer their patients a more personalized medical care.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- What Are Some New Developments in Prostate Cancer Diagnosis?
- The Diagnostic Value of Prostate-specific Antigen and the of Routine Laboratory Examination for Early Detection
- The prostate specific antigen in detection of the prostate cancer
- Change of serum prostate specific antigen values after radiation therapy in prostate cancer
- High-Grade Prostatic Intraepithelial Neoplasia
